To verify the relationship between METTL3, FGFR3 and antitumor sensitivity of anlotinib in vivo, we explored the expression level of METTL3 and FGFR3 of tumor tissues from eight previously established OSCC PDX models [16]. Here, FGFR3 is linked to neoplasm.